Loading...
NPI 1346667870 · Aurora, CO · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jorge Monge Urrea is a hematology & oncology physician provider located in Aurora, Colorado. This profile covers 19 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jorge Monge Urrea |
| Address | 1665 Aurora Ct |
| City | Aurora |
| State | CO |
| ZIP | 80045 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | March 21, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.9M |
| Medicaid | $18.9K |
This provider’s billing is Medicare-dominant: Total Medicare revenue is $1.9M compared with total Medicaid revenue of $18.9K, so Medicare accounts for the overwhelming share of reported reimbursement and Medicaid is effectively a secondary, very small payer for this clinician. The scale difference suggests the provider’s commercial/Medicare-facing operations are the primary business driver while Medicaid represents a minimal portion of volume and dollars.
Medicare revenue is highly concentrated in a very small set of drug-administration codes: the precomputed top 3 Medicare codes account for 87.4% of this provider’s Medicare revenue. Those three contributors are led by J9144 at $1.4M (73.9% of Medicare revenue), followed by J0897 at $153.4K (8.3%) and J1568 at $96.2K (5.2%), indicating that a few high-use biologic or infusion items dominate payer receipts.
The code mix and top billed items point to an infusion- and injectable-focused hematology/oncology practice. J9144 (daratumumab with hyaluronidase) is the single largest revenue driver, and notable use of J0897 (denosumab) plus immune globulin codes J1568 and J1561 indicates regular administration of oncology-targeted monoclonal antibody and IVIG therapies rather than a purely clinic-visit revenue model. Operationally, this pattern is consistent with an office-based infusion suite or infusion clinic workflow.
J9144 is an outlier relative to national peers: it ranks #5 of 615 providers nationally (99th percentile; extreme outlier), which positions this provider as a major national-level reporter for daratumumab administration. By contrast, J0897 ranks #1458 of 10057 (86th percentile; typical, unremarkable) and J1568 ranks #207 of 381 (46th percentile; typical, unremarkable), so the provider’s market dominance is highly specific to J9144 rather than across all high-cost injectable drugs.
Evaluation-and-management activity is present but secondary to drug revenue: 99215 generated $52.8K (2.9% of Medicare revenue) from 334 claims and ranks #4671 of 145531 providers nationally (97th percentile; notably above typical national volume). This suggests a substantive ambulatory follow-up and complexity-management role consistent with ongoing oncology care, although E/M dollars remain a minority compared with infusion/drug payments.
On the Medicaid side the revenue picture is compact and clinic-visit centric: the precomputed top 3 Medicaid codes account for 100.0% of Medicaid revenue, with 99215 producing $15.5K (82.4% of Medicaid revenue) and 99214 producing $2.8K (14.7%). In-state rank for Medicaid 99215 is #336 of 724 (54th percentile; typical, unremarkable), indicating a modest statewide presence on Medicaid compared with the provider’s Medicare activity.
There is a notable Medicaid reporting anomaly in the dataset: code 36415 shows 450 claims with $0 avg paid/claim and $0 revenue (0.0% of Medicaid revenue) while still ranking #277 of 680 in-state (59th percentile). This pattern could reflect bundling, crosswalked billing, or a data/reporting artifact and is a data point worth following up on when reconciling encounter-level payments or contract-level reimbursement rules.
The provider has an established NPI tenure, enumerated on 2014-03-21 (~12 years ago), which aligns with developing the referral relationships and operational infrastructure needed to sustain high-volume specialty drug administration such as the observed J9144 activity. Tenure combined with the extreme outlier status on a leading biologic suggests an entrenched, specialized infusion operation rather than a newly established practice.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
19 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 36,000 | $40 | $1.4M |
| J0897 | Injection, denosumab, 1 mg | 8,520 | $20 | $153.4K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 2,830 | $30 | $96.2K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 1,560 | $40 | $59.3K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 330 | $160 | $52.8K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 250 | $110 | $26.5K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 340 | $70 | $24.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 180 | $120 | $21K |
| J9041 | Injection, bortezomib, 0.1 mg | 4,250 | $1 | $17K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 70 | $130 | $8.3K |
Showing 1–10 of 19
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
19 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J1561 | 3 | 10 | 15,520 | $40 | $517.8K |
| J9144 | 1 | 20 | 7,560 | $40 | $354.8K |
| J1568 | 14 | 30 | 2,240 | $30 | $101.5K |
| J0897 | 8 | 140 | 2,580 | $20 | $68.8K |
| 96413 | 93 | 140 | 130 | $100 | $19.7K |
| J9041 | 3 | 10 | 4,300 | $1 | $17.5K |
| 99214 | 2,129 | 8,160 | 80 | $80 | $11.3K |
| 99233 | 254 | 1,890 | 70 | $90 | $11K |
| 96365 | 78 | 170 | 100 | $50 | $9.5K |
| 99215 | 81 | 3,230 | 40 | $110 | $8.1K |
Showing 1–10 of 19
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 160 | $100 | $15.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 40 | $70 | $2.8K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 20 | $30 | $540 |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 450 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Colorado providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Colorado median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 2,218 | 2,630 | 430 | $90 | $268.2K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 336 | 720 | 130 | $100 | $110K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 9 | 10 | 60 | $150 | $23.8K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 277 | 680 | 260 | $1 | $4.3K |
Other providers in the same ZIP code as Jorge Monge Urrea, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Prosthetic & Orthotic Group Pediatric Specialists - Colorado LLC | CO | Prosthetic/Orthotic Supplier | $0 | $7.3M |
| Children's Optical, LLC | CO | Pediatric Optometrist | $0 | $6.4M |
| Rmchs Management | CO | Pediatric Dentistry | $0 | $4.4M |
| University Physicians Incorporated | CO | Clinical Medical Laboratory | $271.4K | $3.4M |
| Marisa Lau | CO | Ophthalmology Physician | $2M | $0 |
| University Physicians Incorporated | CO | Clinical Medical Laboratory | $509.9K | $886.9K |
| Rachel Chen | CO | Retina Specialist (Ophthalmology) Physician | $1M | $0 |
| Jeffrey Olson | CO | Ophthalmology Physician | $983.2K | $0 |
| Signal Diagnostics LLC | CO | Clinical Medical Laboratory | $976K | $0 |
| Ali Shahabi | CO | Cytopathology Physician | $859.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.